P-21 (also written P021; sequence Ac-DGGLAG-NH2, CAS 1246751-68-7) is a synthetic adamantane-modified tetrapeptide derived from the active region of human ciliary neurotrophic factor (CNTF). It was developed in Khalid Iqbal's lab at the New York State Institute for Basic Research, as part of a program that pared the neurotrophic activity of Cerebrolysin down to a single small, defined molecule. In nootropic and longevity communities it is discussed almost entirely for one proposed property: stimulating new neuron growth (neurogenesis) in the hippocampus while reducing tau pathology. This article sorts those claims by source class — what was demonstrated in animals or cell culture versus what is purely community-reported.
The evidence context is worth stating up front. The P-21 research base is a coherent body of rodent work published roughly 2010–2019, and unlike the Dihexa literature, it carries no retractions or integrity flags. But it is entirely preclinical, much of it from the single originating lab, and none of it has been reproduced in humans. There are no published human clinical trials of P-21, no human pharmacokinetic data, and no characterized human dose. Each claimed benefit below is labeled by its evidence source so the reader can weigh it directly.
Research-context information only. P-21 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
How P-21 Works (Proposed — Preclinical)
The proposed mechanism, as described in the originating literature, is that P-21 increases BDNF (brain-derived neurotrophic factor) expression and inhibits leukemia inhibitory factor (LIF) signaling, with downstream effects that include reduced GSK-3β activity and increased phospho-CREB. That cascade is reported to drive dentate gyrus neurogenesis and synaptic plasticity. The "CNTF-mimetic" shorthand repeated in vendor copy is accurate as to the molecule's origin — it derives from a CNTF active region — but the procognitive effect the authors describe runs largely through a BDNF-mediated pathway rather than classical CNTF receptor signaling.
The adamantane moiety was added to improve metabolic stability and blood-brain-barrier penetration relative to the bare peptide. Khatoon et al. 2015 (PMID 26401692) reported that P021 was BBB-permeable in aged rats and lowered total tau in brain and cerebrospinal fluid. All of this mechanistic work is preclinical — rodent and in-vitro. No human mechanistic or pharmacokinetic data exists, so the pathway above should be read as a proposed mechanism demonstrated in animal models, not an established human effect. Dose and route discussion belongs to the community sources covered later, not to any validated human protocol.
Neurogenesis and Memory in Animal Models (Preclinical — Strongest Evidence)
The strongest and most consistent benefit in the P-21 record is improved learning and memory alongside increased neurogenesis in rodents. The foundational paper, Li et al. 2010 (PMID 20600002), introduced P21 and reported that peripheral administration enhanced short-term and spatial reference memory and promoted neurogenesis and synaptic plasticity in normal adult mice. Bolognin et al. 2014 (PMID 24702821) extended this to aging: chronic oral P021 was reported to reduce age-dependent decline in learning and memory in aged rats, enhance neurogenesis, and restore synaptic function.
This is the cleanest part of P-21's evidence base, and it is important to frame it accurately. These are rodent studies — in normal mice and in aging models — not human trials, and not a measure of cognitive enhancement in healthy people. They report that P021 improved memory readouts and neurogenesis markers in animals through a stated mechanism. They do not establish that the same holds in humans, where no data exist. Their value is that the direction is consistent across studies and the literature is free of the integrity flags that undermine comparable nootropic compounds.
Ready to buy? The single research-grade source we track for P-21:
